Stock VRCA VERRICA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Verrica Pharmaceuticals Inc.

Equities

VRCA

US92511W1080

Pharmaceuticals

Real-time Estimate Cboe BZX
Other stock markets
 19:22:56 03/05/2024 BST 		5-day change 1st Jan Change
7.14 USD +5.62% Intraday chart for Verrica Pharmaceuticals Inc. +1.82% -4.44%
03-26 Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing MT
03-26 Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA CI

Business Summary

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Number of employees: 100

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Topical Solution of Cantharidin
100.0 %
9 100.0 % 5 100.0 % -43.27%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
9 100.0 % 5 100.0 % -43.27%

Managers

Managers TitleAgeSince
Ted White CEO
 Chief Executive Officer 59 30/11/17
Terence Kohler DFI
 Director of Finance/CFO 46 15/07/21
Christopher Hayes CMP
 Compliance Officer 60 31/08/18
Gary Goldenberg CTO
 Chief Tech/Sci/R&D Officer 47 30/04/18
Joe Bonaccorso PRN
 Corporate Officer/Principal 60 31/01/18

Members of the board

Members of the board TitleAgeSince
Mark Prygocki BRD
 Director/Board Member 58 30/04/18
Paul Manning CHM
 Chairman 68 30/11/15
Craig Ballaron BRD
 Director/Board Member 63 12/06/19
Sean Stalfort BRD
 Director/Board Member 54 30/11/15
Ted White CEO
 Chief Executive Officer 59 30/11/17
Lawrence Eichenfield BRD
 Director/Board Member 66 30/06/20
Gary Goldenberg CTO
 Chief Tech/Sci/R&D Officer 47 30/04/18
Diem Nguyen BRD
 Director/Board Member 52 08/06/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 42,525,197 18,479,846 ( 43.46 %) 105,144 ( 0.2473 %) 43.46 %

Shareholders

NameEquities%Valuation
Paul Manning
36.75 %
15,589,481 36.75 % 92 M $
Perceptive Advisors LLC
16.74 %
7,099,182 16.74 % 42 M $
Avoro Capital Advisor LLC
9.430 %
3,999,999 9.430 % 24 M $
Fidelity Management & Research Co. LLC
3.558 %
1,509,063 3.558 % 9 M $
Vanguard Fiduciary Trust Co.
2.973 %
1,261,101 2.973 % 7 M $
BlackRock Advisors LLC
2.552 %
1,082,727 2.552 % 6 M $
Sean Stalfort
1.651 %
700,205 1.651 % 4 M $
Geode Capital Management LLC
1.013 %
429,677 1.013 % 3 M $
STATE STREET CORPORATION
0.9177 %
389,267 0.9177 % 2 M $
BML Capital Management LLC
0.4243 %
180,000 0.4243 % 1 M $

Company contact information

Verrica Pharmaceuticals, Inc.

44 West Gay Street Suite 400

19380, West Chester

+484 453 3300

http://www.verrica.com
address Verrica Pharmaceuticals Inc.(VRCA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Ratings for Verrica Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.76 USD
Average target price
13.6 USD
Spread / Average Target
+101.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
VERRICA PHARMACEUTICALS INC. Stock Verrica Pharmaceuticals Inc.
-4.44% 287M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.11% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.97% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.26% 325B
ABBVIE INC. Stock AbbVie Inc.
+5.38% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
NOVARTIS AG Stock Novartis AG
+3.65% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.99% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. VRCA Stock
  4. Company Verrica Pharmaceuticals Inc.